Johnson & Johnson (JNJ)
147.16
+1.42
(+0.97%)
USD |
NYSE |
Apr 19, 13:12
Johnson & Johnson Accounts Payable (Quarterly): 9.632B for Dec. 31, 2023
Accounts Payable (Quarterly) Chart
Historical Accounts Payable (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 9.632B |
September 30, 2023 | 8.355B |
June 30, 2023 | 10.44B |
March 31, 2023 | 9.909B |
December 31, 2022 | 9.889B |
September 30, 2022 | 10.15B |
June 30, 2022 | 9.765B |
March 31, 2022 | 9.309B |
December 31, 2021 | 11.06B |
September 30, 2021 | 8.961B |
June 30, 2021 | 8.704B |
March 31, 2021 | 8.503B |
December 31, 2020 | 9.505B |
September 30, 2020 | 7.044B |
June 30, 2020 | 6.765B |
March 31, 2020 | 7.411B |
December 31, 2019 | 8.544B |
September 30, 2019 | 7.491B |
June 30, 2019 | 6.912B |
March 31, 2019 | 6.923B |
December 31, 2018 | 7.537B |
September 30, 2018 | 7.00B |
June 30, 2018 | 6.516B |
March 31, 2018 | 6.443B |
December 31, 2017 | 7.31B |
Date | Value |
---|---|
September 30, 2017 | 6.39B |
June 30, 2017 | 6.135B |
March 31, 2017 | 6.082B |
December 31, 2016 | 6.918B |
September 30, 2016 | 5.971B |
June 30, 2016 | 6.061B |
March 31, 2016 | 5.965B |
December 31, 2015 | 6.668B |
September 30, 2015 | 5.928B |
June 30, 2015 | 6.14B |
March 31, 2015 | 6.719B |
December 31, 2014 | 7.633B |
September 30, 2014 | 6.603B |
June 30, 2014 | 6.193B |
March 31, 2014 | 6.113B |
December 31, 2013 | 6.266B |
September 30, 2013 | 6.055B |
June 30, 2013 | 5.687B |
March 31, 2013 | 5.372B |
December 31, 2012 | 5.831B |
September 30, 2012 | 5.344B |
June 30, 2012 | 5.145B |
March 31, 2012 | 5.085B |
December 31, 2011 | 5.725B |
September 30, 2011 | 5.73B |
Accounts Payable Definition
Accounting terminology for money that a company owes to vendors for services or products that it purchased on credit. Accounts payable appear on the balance sheet as a current liability.
Accounts Payable (Quarterly) Range, Past 5 Years
6.765B
Minimum
Jun 2020
11.06B
Maximum
Dec 2021
8.861B
Average
8.961B
Median
Sep 2021
Accounts Payable (Quarterly) Benchmarks
Amgen Inc | 1.59B |
Gilead Sciences Inc | 550.00M |
Eli Lilly and Co | 2.599B |
Merck & Co Inc | 3.922B |
Shockwave Medical Inc | 8.868M |